Generic Name and Formulations:
Hydrocodone bitartrate, acetaminophen; 5mg/325mg, 7.5mg/325mg, 10mg/325mg; scored tabs.
Indications for NORCO:
Moderate to moderately severe pain.
5mg/325mg: 1–2 tabs every 4–6 hrs as needed. 7.5mg/325mg, 10mg/325mg: 1 tab every 4–6 hrs as needed; max 6 tabs/day.
Head injury. Increased intracranial pressure. Acute abdomen. Impaired renal, hepatic, thyroid, pulmonary, or adrenocortical function. GI or GU obstruction. Asthma. Drug abusers. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Potentiation with alcohol, other CNS depressants, MAOIs, tricyclic antidepressants, antihistamines, anticholinergics, antipsychotics, antianxiety agents (reduce dose of either or both drugs if used together). Acetaminophen may cause false (+) urinary 5-hydroxyindoleacetic acid test.
Opioid + analgesic.
Lightheadedness, CNS/respiratory depression, nausea, vomiting, constipation, urinary retention, rash, abuse potential; hepatotoxicity (overdosage).
Tabs 5/325, 7.5/325—100; 10/325—100, 500
Endocrinology Advisor Articles
- Imaging Studies in Hypothyroidism Evaluation Linked to Unnecessary Risks
- Transoral Endoscopic Thyroidectomy Vestibular Approach: Safety and Outcomes
- Once-Weekly Omarigliptin Improves Glycemic Control in Type 2 Diabetes
- Insulin Glargine Associated With Breast Cancer Risk in T2D
- High Grip Strength Associated With Lower Risk for Diabetes-Related AEs
- Update on Vitamin D and Calcium Supplements for Reducing Fracture Risk
- Bariatric Surgery: An Effective Treatment for Type 2 Diabetes
- Lower Risk for SGLT2i-Associated Genitourinary Infection With DPP-4i
- Severe Hypoglycemia Associated With Increased Mortality Risk in T2D
- Efficacy of CGM in Preterm Infants of Mothers With Diabetes
- Increased Risk of Diabetes, Post-Diabetes Pneumonia for Patients With COPD
- Pancreatic Exocrine Dysfunction Occurs After Islet Autoimmunity in T1D
- T2D in African American Women Ups ER-negative Breast Cancer Risk
- High-Sensitivity CRP and LDL-C Predictive of Subsequent MACE in T2D
- Risks Associated With Denosumab Discontinuation